163 related articles for article (PubMed ID: 1899152)
1. Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial.
Waid TH; Lucas BA; Thompson JS; Munch LC; Brown S; Kryscio R; Prebeck R; VanHoy MA; Jezek D
Transplant Proc; 1991 Feb; 23(1 Pt 2):1062-5. PubMed ID: 1899152
[No Abstract] [Full Text] [Related]
2. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation.
Frenken LA; Hoitsma AJ; Tax WJ; Koene RA
Transplant Proc; 1991 Feb; 23(1 Pt 2):1072-3. PubMed ID: 1824887
[No Abstract] [Full Text] [Related]
4. A prospective randomized comparison of prophylactic ALG and OKT3 in cadaver kidney allograft recipients.
Hanto DW; Jendrisak MD; McCullough CS; So SK; Marsh JW; Rush T; Michalski S; Phelan D; Mohanakumar T
Transplant Proc; 1991 Feb; 23(1 Pt 2):1050-1. PubMed ID: 1899150
[No Abstract] [Full Text] [Related]
5. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients.
Waid TH; Lucas BA; Thompson JS; Brown SA; Munch L; Prebeck RJ; Jezek D
Transplantation; 1992 Jan; 53(1):80-6. PubMed ID: 1531095
[TBL] [Abstract][Full Text] [Related]
6. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation.
Knechtle SJ; Pirsch JD; Groshek M; Reed A; D'Alessandro AM; Kalayoglu M; Belzer FO; Sollinger HW
Transplant Proc; 1991 Feb; 23(1 Pt 2):1581-2. PubMed ID: 1846478
[No Abstract] [Full Text] [Related]
7. First and second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection followed by testing for anti-OKT3 IgM and/or IgG immunization.
Birkeland SA; Bach JF; Chatenoud L; Jørgensen KA; Strate M; Elbirk A; Rohr N; Svendsen V
Transplant Proc; 1990 Feb; 22(1):221-2. PubMed ID: 2106740
[No Abstract] [Full Text] [Related]
8. Induction immunotherapy in heart transplantation with T10B9.1A-31: a phase I study.
Waid TH; Thompson JS; McKeown JW; Brown SA; Sekela ME
J Heart Lung Transplant; 1997 Sep; 16(9):913-6. PubMed ID: 9322140
[TBL] [Abstract][Full Text] [Related]
9. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
[No Abstract] [Full Text] [Related]
10. The effect of induction ALG (MALG) on the outcome of steroid-resistant rejection treated with OKT3 in renal transplant patients.
Chiu A; Landsberg D; Cameron EC; Manson AD; Shackleton C
Transplant Proc; 1991 Feb; 23(1 Pt 2):1039-40. PubMed ID: 1899146
[No Abstract] [Full Text] [Related]
11. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation.
Kirkman RL; Shapiro ME; Carpenter CB; McKay DB; Milford EL; Ramos EL; Tilney NL; Waldmann TA; Zimmerman CE; Strom TB
Transplant Proc; 1991 Feb; 23(1 Pt 2):1066-7. PubMed ID: 1989150
[No Abstract] [Full Text] [Related]
12. Immunologic monitoring with Orthoclone OKT3 therapy.
Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
[TBL] [Abstract][Full Text] [Related]
13. OKT3 resistant rejection in liver transplant patients.
Sutherland F; Lazarovits A; Aboujaoude M; Grant D; Ghent C; Sommerauer J; Wall W
Transplant Proc; 1991 Feb; 23(1 Pt 2):1413-4. PubMed ID: 1824898
[No Abstract] [Full Text] [Related]
14. MALG vs OKT3 following renal transplantation: a randomized prospective trial.
Frey DJ; Matas AJ; Gillingham KJ; Canafax D; Payne WD; Dunn DL; Sutherland DE; Najarian JS
Transplant Proc; 1991 Feb; 23(1 Pt 2):1048-9. PubMed ID: 1899149
[No Abstract] [Full Text] [Related]
15. Orthoclone OKT3 as rescue treatment for steroid-resistant and recurrent acute rejection in clinical renal transplantation.
Tvedegaard E; Olgaard K
Transplant Proc; 1990 Feb; 22(1):217-8. PubMed ID: 2106738
[No Abstract] [Full Text] [Related]
16. Acute cellular rejection during effective early prophylactic OKT3 monoclonal antibody treatment after renal transplantation.
Haak HH; Weening JJ; Rischen-Vos J; Daha MR; van Es LA; van der Woude FJ
Transplantation; 1989 Aug; 48(2):352-4. PubMed ID: 2526973
[No Abstract] [Full Text] [Related]
17. Immunological follow-up of renal allograft recipients treated with the BMA 031 (anti-TCR) monoclonal antibody.
Chatenoud L; Ferran C; Legendre C; Kurrle R; Kreis H; Bach JF
Transplant Proc; 1990 Aug; 22(4):1787-8. PubMed ID: 2117809
[No Abstract] [Full Text] [Related]
18. Acute renal allograft rejection: the role of monoclonal antibodies in treatment: experience with orthoclonal anti-T3 cell antibody.
McLigeyo SO; Notghi A; Anderton JL; Dick J
East Afr Med J; 1990 Sep; 67(9):667-73. PubMed ID: 2123786
[TBL] [Abstract][Full Text] [Related]
19. T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action.
Brown SA; Lucas BA; Waid TH; McKeown JW; Barve S; Jackson LR; Thompson JS
Clin Transplant; 1996 Dec; 10(6 Pt 2):607-13. PubMed ID: 8996751
[TBL] [Abstract][Full Text] [Related]
20. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
Goldstein G
Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
[No Abstract] [Full Text] [Related]
[Next] [New Search]
